1. Home
  2. STAA vs DSGN Comparison

STAA vs DSGN Comparison

Compare STAA & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo STAAR Surgical Company

STAA

STAAR Surgical Company

HOLD

Current Price

$32.54

Market Cap

867.9M

Sector

Health Care

ML Signal

HOLD

Logo Design Therapeutics Inc.

DSGN

Design Therapeutics Inc.

HOLD

Current Price

$11.07

Market Cap

819.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
STAA
DSGN
Founded
1982
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Ophthalmic Goods
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
867.9M
819.6M
IPO Year
1995
2021

Fundamental Metrics

Financial Performance
Metric
STAA
DSGN
Price
$32.54
$11.07
Analyst Decision
Buy
Strong Buy
Analyst Count
9
4
Target Price
$22.81
$15.25
AVG Volume (30 Days)
874.7K
1.1M
Earning Date
05-12-2026
04-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.10
N/A
Revenue
$239,442,000.00
N/A
Revenue This Year
$30.82
N/A
Revenue Next Year
$8.41
N/A
P/E Ratio
$328.05
N/A
Revenue Growth
N/A
N/A
52 Week Low
$15.59
$3.33
52 Week High
$35.87
$17.25

Technical Indicators

Market Signals
Indicator
STAA
DSGN
Relative Strength Index (RSI) 77.35 40.09
Support Level $23.75 $9.25
Resistance Level $35.87 $13.54
Average True Range (ATR) 1.50 1.32
MACD 0.25 -0.52
Stochastic Oscillator 66.12 16.83

Price Performance

Historical Comparison
STAA
DSGN

About STAA STAAR Surgical Company

Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of its sales are generated from the ophthalmic surgical product segment.

About DSGN Design Therapeutics Inc.

Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.

Share on Social Networks: